Related Experiment Video

Updated: Mar 7, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

Adrianus J de Langen1, Egbert F Smit2

  • 1Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands.

Therapeutic Advances in Medical Oncology
|February 17, 2017
PubMed

Insights

BRAF mutations in lung adenocarcinoma present a targetable pathway. This review covers BRAF-mutated non-small cell lung cancer (NSCLC) treatment, resistance, and overcoming challenges with BRAF and MEK inhibitors.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Lung adenocarcinoma exhibits frequent somatic mutations and genomic alterations.
  • Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have guided targeted therapies in NSCLC.
  • BRAF mutations occur in approximately 4% of non-small cell lung cancer (NSCLC) cases.

Purpose of the Study:

  • To review the latest evidence on treating BRAF-mutated NSCLC.
  • To discuss tumor biology, targeted therapies, and resistance mechanisms.
  • To explore strategies for overcoming therapeutic resistance in BRAF-mutated NSCLC.

Main Methods:

  • Literature review of recent studies on BRAF-mutated NSCLC.
  • Analysis of clinical trial data for BRAF and MEK inhibitors.
  • Examination of molecular mechanisms of resistance to targeted therapies.

Main Results:

  • BRAF and MEK inhibitors show promise in treating BRAF-mutated NSCLC, with approvals in melanoma.
  • Understanding tumor biology is crucial for effective targeted treatment.
  • Therapeutic resistance is a significant challenge, necessitating further research into overcoming it.

Conclusions:

  • Targeted therapy with BRAF and MEK inhibitors represents a promising avenue for BRAF-mutated NSCLC.
  • Further investigation into resistance mechanisms and novel therapeutic strategies is essential for improving patient outcomes.
  • Personalized medicine approaches based on genetic alterations are transforming NSCLC treatment.
Keywords:
BRAFNSCLCTKI

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K